公开(公告)号：US07278420B2

公开(公告)日：2007-10-09

申请号：US10666290

申请日：2003-09-19

申请人： Arjunan Ganesh ,  Valerie E. Armstead ,  Michael J. Williams

发明人： Arjunan Ganesh ,  Valerie E. Armstead ,  Michael J. Williams

IPC分类号： A61M16/08

CPC分类号： A61M16/04 ,  A61M16/0463 ,  A61M16/0493 ,  A61M16/0495 ,  A61M16/085 ,  A61M2210/0656 ,  A61M2230/432

摘要： An oropharyngeal device for insertion into the mouth of a patient. The device includes a body having a distal end and a proximal end with a flange formed at the proximal end. The distal end is inserted into the mouth until the flange is disposed outside and adjacent to the patient's mouth. The flange keeps the proximal device from entering the mouth. The body is sized such that the distal end of the body is disposed within the pharynx above the epiglottis. The device includes a channel that forms an airway between the ends. The device also includes at least three separate conduits integrated into the body for administering oxygen, suctioning, and for assessing ventilation thorough end-tidal carbon dioxide monitoring. The conduits for oxygenation and suctioning extend through the body between its proximal and distal ends. The conduit for end-tidal carbon dioxide monitoring terminates within the channel.

摘要翻译： 用于插入患者口腔的口咽装置。 该装置包括具有远端和近端的主体，该近端具有形成在近端的凸缘。 将远端插入口中，直到凸缘设置在患者口腔的外侧和邻近处。 法兰保持近端装置不进入口。 身体的大小使得身体的远端设置在会厌上方的咽内。 该装置包括在两端之间形成气道的通道。 该装置还包括集成到主体中的至少三个分离的管道，用于施用氧气，抽吸和用于通过彻底的潮气二氧化碳监测来评估通风。 用于氧合和抽吸的导管在其近端和远端之间延伸穿过身体。 用于潮汐二氧化碳监测的管道在通道内终止。

公开(公告)号：US06974571B2

公开(公告)日：2005-12-13

申请号：US08913918

申请日：1996-03-28

申请人： Darwin J. Prockop ,  Ruth F. Pereira ,  Dennis B. Leeper ,  Michael D. O'Hara ,  Joseph Kulkosky ,  Donald Phinney ,  Alexey Laptev

发明人： Darwin J. Prockop ,  Ruth F. Pereira ,  Dennis B. Leeper ,  Michael D. O'Hara ,  Joseph Kulkosky ,  Donald Phinney ,  Alexey Laptev

IPC分类号： A61K35/12 ,  A61K35/28 ,  A61K38/00 ,  A61K48/00 ,  C07K14/47 ,  C07K14/61 ,  C07K14/745 ,  C07K14/78 ,  C12M3/06 ,  C12N5/0775 ,  C12N15/00

CPC分类号： A61K48/005 ,  A61K35/28 ,  A61K38/00 ,  A61K48/00 ,  A61K48/0025 ,  A61K2035/124 ,  A61K2035/128 ,  C07K14/4702 ,  C07K14/61 ,  C07K14/745 ,  C07K14/78 ,  C12N5/0663 ,  C12N2502/1394 ,  C12N2799/027

摘要： Methods of treating patients who are suffering from a disease, disorder or condition characterized by a bone cartilage or lung defect are disclosed. The methods comprising the step of intravenous administration of stromal cells isolated from normal syngeneic individuals or intravenous administration of stromal cells isolated from the patient subsequent to correction of the genetic defect in the isolated cells. Implant devices comprising a container that has at least one membrane surface and stromal cells isolated from bone marrow that comprise a gene construct are disclosed. The gene construct in the stromal cells comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells. Methods of treating individuals with diseases, disorders or conditions which can be treated with a beneficial protein, including diseases, disorders or conditions characterized by gene defects are disclosed. The methods comprise introducing into such individuals, stromal cells that are administered in a manner that physically isolates them from the recipient's immune system and that comprise a gene construct that comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells.

摘要翻译： 公开了治疗患有由骨软骨或肺缺损特征的疾病，病症或状况的患者的方法。 所述方法包括静脉内施用从正常同基因个体分离的基质细胞的步骤或在校正分离的细胞中的遗传缺陷后从患者静脉内施用分离的基质细胞。 公开了包含具有至少一个膜表面的容器和包含基因构建体的从骨髓分离的基质细胞的植入装置。 基质细胞中的基因构建体包含编码与在基质细胞中起作用的调节元件可操作地连接的有益蛋白质的核苷酸序列。 公开了治疗可以用有益蛋白质治疗的疾病，病症或病症的个体的方法，包括疾病，病症或基因缺陷表征的病症。 所述方法包括向这些个体引入基质细胞，所述基质细胞以将物质从接受者的免疫系统分离的方式施用，并且包含基因构建体，所述基因构建体包含编码有益蛋白的核苷酸序列，所述有益蛋白质可操作地连接于在基质中起作用的调控元件 细胞。

公开(公告)号：US20050266443A1

公开(公告)日：2005-12-01

申请号：US11093746

申请日：2005-03-30

申请人： Carlo Croce ,  George Calin

发明人： Carlo Croce ,  George Calin

IPC分类号： C07H21/04 ,  C07K14/47 ,  C07K14/525 ,  C12P21/06 ,  C12Q1/37 ,  C12Q1/68 ,  G01N33/574

CPC分类号： C07K14/4703 ,  C12Q1/37 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/154 ,  G01N33/574 ,  G01N33/57426 ,  G01N2333/96472 ,  G01N2510/00

摘要： The present invention relates to the identification and cloning of ARTS1, a novel tumor suppressor gene. The invention further encompasses isolated proteins encoded by ARTS1, methods of making and using the same, methods of diagnosing the presence of, or prediposition for, a cancer associated with a defective ARTS1 gene or gene product, and methods of treating or preventing cancers associated with a defective ARTS1 gene or gene product.

摘要翻译： 本发明涉及鉴定和克隆ARTS1，一种新的肿瘤抑制基因。 本发明还包括由ARTS1编码的分离的蛋白质，其制备和使用它们的方法，诊断与缺陷型ARTS1基因或基因产物相关的癌症的存在或预期的方法，以及治疗或预防与ARTS1基因相关的癌症的方法 缺失的ARTS1基因或基因产物。

公开(公告)号：US06897296B2

公开(公告)日：2005-05-24

申请号：US10668955

申请日：2003-09-22

申请人： Emad S. Alnemri ,  Teresa Fernandes-Alnemri ,  Gerald Litwack ,  Robert Armstrong ,  Kevin Tomaselli

发明人： Emad S. Alnemri ,  Teresa Fernandes-Alnemri ,  Gerald Litwack ,  Robert Armstrong ,  Kevin Tomaselli

IPC分类号： C12N15/09 ,  A61K38/00 ,  C12N9/64 ,  C12N15/57 ,  C07K16/00

CPC分类号： C12N9/6475 ,  A61K38/00

摘要： The invention provides an isolated gene encoding Mch4 or an isolated gene encoding Mch5 as well as functional fragments thereof. Also provided are isolated nucleic acid sequences encoding Mch4 or Mch5 or functional fragment thereof. The gene or nucleic acid sequences can be single or double stranded nucleic acids corresponding to coding or non-coding strands of the Mch4 or Mch5 nucleotide sequences. Also provided are genes and nucleic acids encoding functional fragments such as the FADD-like domains Mch4A, Mch4B, Mch5A and Mch5B. Isolated Mch4 or Mch5 polypeptides or functional fragments thereof including the FADD-like domains Mch4A, Mch4B, Mch5A and Mch5B are also provided.

摘要翻译： 本发明提供编码Mch4的分离基因或编码Mch5的分离基因及其功能片段。 还提供了编码Mch4或Mch5的分离的核酸序列或其功能片段。 基因或核酸序列可以是对应于Mch4或Mch5核苷酸序列的编码链或非编码链的单链或双链核酸。 还提供了编码功能片段的基因和核酸，例如FADD样结构域Mch4A，Mch4B，Mch5A和Mch5B。 还提供了分离的Mch4或Mch5多肽或其功能片段，其包括FADD样结构域Mch4A，Mch4B，Mch5A和Mch5B。

公开(公告)号：US20050085417A1

公开(公告)日：2005-04-21

申请号：US10688821

申请日：2003-10-16

申请人： Eric Wickstrom ,  Mathew Thakur

发明人： Eric Wickstrom ,  Mathew Thakur

IPC分类号： A61K51/08 ,  A61K51/12 ,  C12N15/11 ,  C12N15/113 ,  A61K48/00

CPC分类号： C12N15/1135 ,  A61K51/088 ,  A61K51/1268 ,  B82Y5/00 ,  C12N15/111 ,  C12N15/1138 ,  C12N2310/3181 ,  C12N2310/3513 ,  C12N2310/3517 ,  C12N2320/32

摘要： Compounds comprising a diagnostic or therapeutic moiety can be retained inside a cell by conjugating the moiety to at least one PNA that is targeted to the transcripts from a gene of interest. The diagnostic or therapeutic moiety is also conjugated to at least one targeting moiety specific for an extracellular receptor or other cell surface molecule. The targeting moiety binds to the surface of a cell, and the entire compound is then internalized. Once inside the cell, the PNA portion of the diagnostic or therapeutic compound binds to RNA transcripts in a sequence specific manner. Binding of the PNA to its target RNA transcript retains the compound within the cell. The PNA can be designed to bind to a predetermined nucleic acid sequence from an RNA transcript, for example a mutated or overexpressed sequence that is characteristic of a pathological state.

摘要翻译： 包含诊断或治疗部分的化合物可以通过将该部分与靶向目的基因的转录物的至少一种PNA结合而保留在细胞内。 诊断或治疗部分还与至少一个对细胞外受体或其他细胞表面分子特异性的靶向部分缀合。 靶向部分结合细胞的表面，然后将整个化合物内化。 一旦在细胞内，诊断或治疗化合物的PNA部分以序列特异性方式结合RNA转录物。 PNA与其靶RNA转录物的结合将该化合物保留在细胞内。 PNA可被设计成从RNA转录物例如具有病理状态特征的突变或过表达序列结合预定的核酸序列。

公开(公告)号：US20050020530A1

公开(公告)日：2005-01-27

申请号：US10937824

申请日：2004-09-09

申请人： Jay Schneider

发明人： Jay Schneider

IPC分类号： C12N15/09 ,  A61K31/7088 ,  A61K38/00 ,  A61K48/00 ,  A61P25/16 ,  C12N15/113

CPC分类号： A61K31/711 ,  A61K38/00 ,  C12N15/1137 ,  C12N2310/152 ,  C12N2310/315

摘要： The present invention relates to a method of treatment of Parkinson's disease, and to the use of antisense oligonucleotides or triplex oligonucleotides introduced into targeted brain structures to decrease the function of brain circuits known to be overactive in the Parkinsonian brain. Antisense or triplex oligonucleotides are targeted to the internal globus pallidus and/or substantia nigra pars reticulata (SNr) where the expression of glutamic acid decarboxylase (GAD67, GAD65, or a combination of the two isoforms) is downregulated. The present invention also relates to a method of treatment of Parkinson's disease where antisense or triplex oligonucleotides are targeted to the internal globus pallidus and/or substantia nigra pars reticulata for the downregulation of glutamate receptors. The present invention further relates to a method of treatment of Parkinson's disease where antisense or triplex oligonucleotides are targeted to the thalamic motor nuclei for the downregulation of GABA receptors.

摘要翻译： 本发明涉及治疗帕金森病的方法，以及引入靶向脑结构中的反义寡核苷酸或三链寡核苷酸的用途，以降低已知在帕金森病脑中过度活跃的脑电路的功能。 反义或三重寡核苷酸靶向内部苍白球和/或黑质浆果（SNr），其中谷氨酸脱羧酶（GAD67，GAD65或两种同种型的组合）的表达下调。 本发明还涉及一种治疗帕金森病的方法，其中反义或三重寡核苷酸针对内部苍白球和/或黑质黑质对谷氨酸受体的下调。 本发明还涉及治疗帕金森病的方法，其中反义或三重寡核苷酸靶向用于下调GABA受体的丘脑运动核。

公开(公告)号：US20040184989A1

公开(公告)日：2004-09-23

申请号：US10769171

申请日：2004-01-30

申请人： Thomas Jefferson University

发明人： Madhukar (Mathew) L. Thakur

IPC分类号： A61M036/14 ,  A61K051/00

CPC分类号： A61K51/0478

摘要： The present invention is a method of injecting a class of lipid soluble radioactive metal chelate compounds for intratumoral treatment of malignant, benign, metastatic, or inoperable tumors. A device for intratumoral injection of such compounds comprises a syringe and attached needle having a closed sharp tip and a plurality of outlets arranged in the need shaft to provide for radial distribution of the injected substance in a volume of tissue.

摘要翻译： 本发明是一种注射一类脂溶性放射性金属螯合物的方法，用于肿瘤内治疗恶性，良性，转移性或不能手术的肿瘤。 用于肿瘤内注射这种化合物的装置包括注射器和连接的针，其具有封闭的尖锐尖端和布置在需要轴中的多个出口以提供注射物质在一定体积的组织中的径向分布。

公开(公告)号：US20040129272A1

公开(公告)日：2004-07-08

申请号：US10666290

申请日：2003-09-19

申请人： Thomas Jefferson University

发明人： Arjunan Ganesh ,  Valerie E. Armstead ,  Michael J. Williams

IPC分类号： A61M016/00 ,  A62B009/06

CPC分类号： A61M16/04 ,  A61M16/0463 ,  A61M16/0493 ,  A61M16/0495 ,  A61M16/085 ,  A61M2210/0656 ,  A61M2230/432

摘要： An oropharyngeal device for insertion into the mouth of a patient. The device includes a body having a distal end and a proximal end with a flange formed at the proximal end. The distal end of the body is inserted into the mouth of the patient until the flange at the proximal end is disposed outside and adjacent to the patient's mouth. The flange keeps the proximal device from entering the mouth. The body is sized such that the distal end of the body is disposed within the pharynx above the epiglottis. The device includes a channel through the body that forms an airway between its proximal and distal ends. The device also includes at least three separate conduits integrated into the body for administering oxygen, suctioning, and for assessing ventilation through end-tidal carbon dioxide monitoring. The conduits for oxygenation and suctioning extend through the body between its proximal and distal ends. The conduit for end-tidal carbon dioxide monitoring extends along and is attached to a side wall of the channel and terminates within the channel.

摘要翻译： 用于插入患者口腔的口咽装置。 该装置包括具有远端和近端的主体，该近端具有形成在近端的凸缘。 身体的远端插入患者的口中，直到近端的凸缘设置在患者口腔的外部和邻近位置。 法兰保持近端装置不进入口。 身体的大小使得身体的远端设置在会厌上方的咽内。 该装置包括通过主体的通道，其在其近端和远端之间形成气道。 该装置还包括集成到主体中的至少三个独立的管道，用于施用氧气，抽吸和通过末端潮气二氧化碳监测来评估通气。 用于氧合和抽吸的导管在其近端和远端之间延伸穿过身体。 用于尾气二氧化碳监测的导管沿着并且附接到通道的侧壁并终止在通道内。

公开(公告)号：US20040092709A1

公开(公告)日：2004-05-13

申请号：US09896784

申请日：2001-06-29

申请人： Thomas Jefferson University

发明人： Robert Martin Townsend ,  Robert Korngold ,  Swati Choksi

IPC分类号： C07K007/08 ,  C07K007/06

CPC分类号： C07K14/7155 ,  A61K38/00

摘要： Peptides which mimic a loop on the null-chain that either interact with a cytokine or a null-chain partner receptor chain of a heterodimeric cytokine receptor are disclosed. The peptides consist of 5-25 amino acids and inhibit signal transduction mediated by cytokine:receptor binding of cytokines that bind to receptors that comprise a null-chain. Pharmaceutical compositions that comprise the peptides are disclosed. Methods of inhibiting signal transduction mediated by cytokine:receptor binding of cytokines that bind to receptors that comprise a null-chain, methods of inhibiting cytokine mediated cell growth, proliferation, function or activity, methods of treating patients suffering from a disease disorder or condition characterized by cytokine mediated cell growth, proliferation, function or activity and methods of preventing a condition characterized by cytokine mediated cell growth, proliferation, function or activity are disclosed.

摘要翻译： 公开了在γ链上模拟与异二聚体细胞因子受体的细胞因子或γ链配偶体受体链相互作用的环的肽。 肽由5-25个氨基酸组成，并抑制细胞因子介导的信号转导：与包含γ链的受体结合的细胞因子的受体结合。 公开了包含肽的药物组合物。 抑制由细胞因子介导的信号转导的方法：结合包含γ链的受体的细胞因子的受体结合，抑制细胞因子介导的细胞生长，增殖，功能或活性的方法，治疗患有疾病病症或状况的患者的方法 通过细胞因子介导的细胞生长，增殖，功能或活性以及预防细胞因子介导的细胞生长，增殖，功能或活性表征的病症的方法。

公开(公告)号：US20030022353A1

公开(公告)日：2003-01-30

申请号：US10171077

申请日：2002-06-12

申请人： Thomas Jefferson University

发明人： Gerald Litwack ,  Emad S. Alnemri ,  Teresa Fernandes-Alnemri

IPC分类号： A61K048/00 ,  C07H021/04 ,  C12P021/02 ,  C12N005/06 ,  C07K016/40 ,  C12N009/64

CPC分类号： C12N9/6475 ,  A61K38/00

摘要： A substantially pure protein that is a member of the apoptotic Ced-3/Ice cysteine protease gene family, Mch2null, and an inactive isoform of it, Mch2null, are disclosed. Isolated nucleic acid molecules that encode Mch2null and Mch2null, respectively, are disclosed. Pharmaceutical compositions comprising a pharmaceutically acceptable carrier in combination with the protein or the nucleic acid molecules are disclosed. Fragments of nucleic acid molecules that encode Mch2null and Mch2null having at least 10 nucleotides and oligonucleotide molecule comprising a nucleotide sequence complimentary to a nucleotide sequence of at least 10 nucleotides are disclosed. Recombinant expression vectors that comprise the nucleic acid molecule that encode Mch2null or Mch2null, and host cells that comprise such recombinant vectors are disclosed. Antibodies that bind to an epitope on Mch2null and/or Mch2null are disclosed. Methods of identifying inhibitors, activators and substrates of Mch2null are disclosed. Antisense compounds and methods of using the same are disclosed.

摘要翻译： 公开了一种基本上纯的蛋白质，其是凋亡Ced-3 / Ice半胱氨酸蛋白酶基因家族Mch2alpha及其非活性同种型Mch2beta的成员。 公开了分别编码Mch2alpha和Mch2beta的分离的核酸分子。 公开了包含与蛋白质或核酸分子组合的药学上可接受的载体的药物组合物。 公开了编码具有至少10个核苷酸的Mch2alpha和Mch2beta的核酸分子的片段和包含与至少10个核苷酸的核苷酸序列互补的核苷酸序列的寡核苷酸分子。 公开了包含编码Mch2alpha或Mch2beta的核酸分子的重组表达载体和包含这种重组载体的宿主细胞。 公开了结合Mch2alpha和/或Mch2beta上的表位的抗体。 公开了鉴定Mch2alpha的抑制剂，活化剂和底物的方法。 公开了反义化合物及其使用方法。